Search clinical trials for: Antineoplastic Agents

Total 188078 results

University of Michigan Rogel Cancer Center
Bristol-Myers Squibb; Eli Lilly and Company

Completed

Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas

Sarcoma

United States
UCB Pharma

Completed

Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease

Systemic Lupus Erythematosus

United States, Poland, Spain, Belgium, India, Ukraine, Brazil, United Kingdom, Hungary, Lithuania, Hong Kong
University of Virginia
Bristol-Myers Squibb; Eli Lilly and Company; Washington University School of...

Unknown

Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma

Cancer of the Cervix

United States
German Breast Group

Completed

Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)

Breast Cancer

Germany
Veeda Oncology
Bristol-Myers Squibb; Sanofi

Completed

A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

Colorectal Cancer

United States
Veeda Oncology
Bristol-Myers Squibb

Completed

Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Janssen-Cilag B.V.

Completed

VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands

Multiple Myeloma | Hematological Neoplasms

Netherlands
Mayo Clinic
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Advanced Cancer

Lymphoma | Leukemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition

United States
Nicola Goekbuget

Recruiting

Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL

Precursor Cell Lymphoblastic Leukemia

Germany
Pfizer

Approved for marketing

Inotuzumab Ozogamicin - PF-05208773
Tianjin Medical University Second Hospital

Recruiting

Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors

Solid Tumor | EGFR Amplification

China
UNICANCER
AstraZeneca

Recruiting

Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax (DURVALUNG)

Small Cell Lung Carcinoma

France
University of Cologne

Not yet recruiting

Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma (INDIE)

Classical Hodgkin Lymphoma

Germany
Oslo University Hospital
St. Olavs Hospital

Recruiting

Drug Concentration Monitoring of Pembrolizumab in Non-Small Cell Lung Cancer Patients (Oncomabs)

NSCLC

Norway
Pfizer
Merck KGaA, Darmstadt, Germany

Active, not recruiting

A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (AVENANCE)

Urothelial Carcinoma

France
Pfizer

Terminated

A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer

Bladder Cancer

Brazil, Argentina
Mayo Clinic
Genentech, Inc.

Active, not recruiting

Obinutuzumab in Primary FSGS

Primary Focal Segmental Glomerulosclerosis

United States
National Cancer Institute, Naples
Azienda Ospedaliera G. Rummo

Active, not recruiting

A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer (PACER)

Metastatic Colorectal Cancer

Italy
Gustave Roussy, Cancer Campus, Grand Paris
Merck Sharp & Dohme LLC

Completed

Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab (PANDORE)

Bladder Cancer

France
Asan Medical Center

Active, not recruiting

Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Korea, Republic of
Ezra Cohen
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

United States
Southern Europe New Drug Organization
Clinical Trial Unit Ente Ospedaliero Cantonale

Completed

Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous Cancer (S10PANI01)

Advanced Head and Neck Squamous Cancer
University Hospital Muenster
Genzyme, a Sanofi Company

Completed

Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01)

Multiple Sclerosis, Relapsing-Remitting

Germany
Abramson Cancer Center of the University of Pennsylvania

Completed

Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas

Follicular Lymphomas | CD19+ Diffuse Large B-cell Lymphomas | Mantle Cell Lymphomas

United States
Peking University Third Hospital

Unknown

Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients

Breast Cancer | Cardiac Toxicity | Antitumor Drugs

China
Nina Bhardwaj

Terminated

Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)

Melanoma

United States
Sunnybrook Health Sciences Centre
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in G3 NEC (NET-001)

Neuroendocrine Carcinoma

Canada
Merck KGaA, Darmstadt, Germany
Pfizer

Approved for marketing

Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)

Metastatic Merkel Cell Carcinoma

France
Deok-Hwan Yang
Roche Pharma AG

Unknown

A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment

Chronic Lymphocytic Leukemia

Korea, Republic of
UCB Pharma

Completed

Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus (EMBODY4)

Systemic Lupus Erythematosus

United States, Brazil, Canada, France, Germany, Hungary, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine, United Kingdom, Australia, Belgium, Bulgaria, Czechia, Estonia, Israel, Korea, Republic of, T... and more
University Hospital Inselspital, Berne
Celgene

Withdrawn

Durvalumab in DLBCL After Autologous Transplant (IDA-D)

Lymphoma, Large B-Cell, Diffuse
Royal Marsden NHS Foundation Trust

Completed

PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer (PROSPECT-C)

Metastatic Colorectal Cancer

United Kingdom
Genentech, Inc.

Completed

A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study

Solid Cancers
Merck KGaA, Darmstadt, Germany

Completed

Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Carcinoma of the Head and Neck

Japan
Peking University

Unknown

Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer

Esophageal Squamous Cell Cancer

China
Mahidol University
Bayer

Terminated

The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL

Peripheral T-Cell Lymphoma

Thailand
Phramongkutklao College of Medicine and Hospital
Bayer

Terminated

The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias

Autoimmune Cytopenias

Thailand
Trial Form Support S.L.
Merck KGaA, Darmstadt, Germany

Unknown

Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.

Oropharyngeal Neoplasms

Spain
Medical University of South Carolina
Ohio State University; University of Texas Southwestern Medical Center; University...

Recruiting

Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices (LOVARB)

Upper Gastrointestinal Bleeding | Liver Cirrhoses | Esophageal Varices | Bleeding Esophageal Varices

United States
Kasr El Aini Hospital

Not yet recruiting

Neoadjuvant Goserelin for Triple Negative Breast Cancer (NeoGONT)

Breast Cancer Triple Negative
Women and Infants Hospital of Rhode Island
Amgen

Terminated

Panitumumab and Gemcitabine in Relapsed Ovarian Cancer (PanGem)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
University of California, San Francisco
Novartis

Terminated

Sandostatin for Patients With Androgen Independent Prostate Cancer

Prostate Cancer

United States
Peregrine Pharmaceuticals

Completed

Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection

Hepatitis C

United States
ImmunoGen, Inc.

Completed

Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer

Small Cell Lung Cancer

United States
M.D. Anderson Cancer Center

Completed

Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma

Prostate Cancer

United States
Samsung Medical Center
Janssen, LP

Unknown

Bortezomib Maintenance in High Risk DLBCL (Borma)

Diffuse Large B Cell Lymphoma

Korea, Republic of
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors

Islet Cell Tumor | Gastrointestinal Carcinoid Tumor

United States
Janssen Pharmaceutical K.K.

Completed

A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients

Multiple Myeloma | Relapse | Refractory
University of Michigan Rogel Cancer Center
GlaxoSmithKline

Completed

Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer

Prostate Cancer

United States
Sinomed Neurovita Technology Inc.

Recruiting

A Registry Study of Intracranial Atherosclerotic Stenosis Treatment by Intracranial Drug-eluting Stenting in China

Intracranial Arteriosclerosis | Drug-Eluting Stents | Intracranial Artery Stenosis | Stenosis Artery

China

Search clinical trials for: Antineoplastic Agents

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations